

August 13, 2026

BSE Limited

P J Towers,
Dalal Street,
Mumbai – 400 001

National Stock Exchange of India Limited

Exchange Plaza, C-1, Block G,
Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051

Scrip Code: 543904

Symbol: MANKIND

Dear Sir/ Madam,

Subject: Intimation of incorporation of a wholly owned subsidiary company in Netherlands

Ref.: Regulation 30 and 51 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“Listing Regulations”)

In continuation of our earlier intimation dated July 11, 2026, and pursuant to Regulations 30 and 51 of the Listing Regulations, we wish to inform you that, as disclosed therein, the proposed wholly owned subsidiary has been incorporated in the Netherlands today, i.e., August 13, 2026, under the name and style of **“Mankind Pharma (Netherlands) B.V.”**

The detailed disclosures as required under the Listing Regulations, read with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026 (“SEBI Circular”), were already provided by the Company in its intimation dated July 11, 2026.

You are requested to kindly take the above information on record.

Thanking You,

Yours Faithfully,

For **Mankind Pharma Limited**

Hitesh Kumar Jain
Company Secretary &
Compliance Officer